B Cell C-Maf Signaling Promotes Tumor Progression in Animal Models of Pancreatic Cancer and Melanoma

Overview

Journal J Immunother Cancer

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2024 Nov 28

PMID 39608978

Authors

Qian Zhong

Hongying Hao

Shu Li

Yongling Ning

Hong Li

Xiaoling Hu

Kelly M McMasters

Jun Yan

Chuanlin Ding

Affiliations

Soon will be listed here.

Abstract

Background: The role of B cells in antitumor immunity remains controversial, with studies suggesting the protumor and antitumor activity. This controversy may be due to the heterogeneity in B cell populations, as the balance among the subtypes may impact tumor progression. The immunosuppressive regulatory B cells (Breg) release interleukin 10 (IL-10) but only represent a minor population. Additionally, tumor-specific antibodies (Abs) also exhibit antitumor and protumor functions dependent on the Ab isotype. Transcription factor c-Maf has been suggested to contribute to the regulation of IL-10 in Breg, but the role of B cell c-Maf signaling in antitumor immunity and regulating Ab responses remains unknown.

Methods: Conditional B cell c-Maf knockout (KO) and control mice were used to establish a KPC pancreatic cancer model and B16.F10 melanoma model. Tumor progression was evaluated. B cell and T cell phenotypes were determined by flow cytometry, mass cytometry, and cytokine/chemokine profiling. Differentially expressed genes in B cells were examined by using RNA sequencing (RNA-seq). Peripheral blood samples were collected from healthy donors and patients with melanoma for B cell phenotyping.

Results: Compared with B cells from the spleen and lymph nodes (LN), B cells in the pancreas exhibited significantly less follicular phenotype and higher IL-10 production in naïve mice. c-Maf deficiency resulted in a significant reduction of CD9 IL-10-producing Breg in the pancreas. Pancreatic ductal adenocarcinoma (PDAC) progression resulted in the accumulation of circulating B cells with the follicular phenotype and less IL-10 production in the pancreas. Notably, B cell c-Maf deficiency delayed PDAC tumor progression and resulted in proinflammatory B cells. Further, tumor volume reduction and increased effective T cells in the tumor-draining LN were observed in B cell c-Maf KO mice in the B16.F10 melanoma model. RNA-seq analysis of isolated B cells revealed that B cell c-Maf signaling modulates immunoglobulin-associated genes and tumor-specific Ab production. We furthermore demonstrated c-Maf-positive B cell subsets and an increase of IL-10-producing B cells after incubation with IL-4 and CD40L in the peripheral blood of patients with melanoma.

Conclusion: Our study highlights that B cell c-Maf signaling drives tumor progression through the modulation of Breg, inflammatory responses, and tumor-specific Ab responses.

References

Lee K, Spata M, Bayne L, Buza E, Durham A, Allman D . Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia. Cancer Discov. 2015; 6(3):256-69. PMC: 4783189. DOI: 10.1158/2159-8290.CD-15-0822. View

Fridman W, Petitprez F, Meylan M, Chen T, Sun C, Roumenina L . B cells and cancer: To B or not to B?. J Exp Med. 2021; 218(1). PMC: 7754675. DOI: 10.1084/jem.20200851. View

Romero D . B cells and TLSs facilitate a response to ICI. Nat Rev Clin Oncol. 2020; 17(4):195. DOI: 10.1038/s41571-020-0338-6. View

Ullman N, Burchard P, Dunne R, Linehan D . Immunologic Strategies in Pancreatic Cancer: Making Tumors . J Clin Oncol. 2022; 40(24):2789-2805. PMC: 9390820. DOI: 10.1200/JCO.21.02616. View

Higgins B, McHeyzer-Williams L, McHeyzer-Williams M . Programming Isotype-Specific Plasma Cell Function. Trends Immunol. 2019; 40(4):345-357. PMC: 6481617. DOI: 10.1016/j.it.2019.01.012. View

Reticker-Flynn N, Zhang W, Belk J, Basto P, Escalante N, Pilarowski G . Lymph node colonization induces tumor-immune tolerance to promote distant metastasis. Cell. 2022; 185(11):1924-1942.e23. PMC: 9149144. DOI: 10.1016/j.cell.2022.04.019. View

Hillion S, Miranda A, Le Dantec C, Boudigou M, Le Pottier L, Cornec D . Maf expression in B cells restricts reactive plasmablast and germinal center B cell expansion. Nat Commun. 2024; 15(1):7982. PMC: 11393457. DOI: 10.1038/s41467-024-52224-6. View

Sharonov G, Serebrovskaya E, Yuzhakova D, Britanova O, Chudakov D . B cells, plasma cells and antibody repertoires in the tumour microenvironment. Nat Rev Immunol. 2020; 20(5):294-307. DOI: 10.1038/s41577-019-0257-x. View

du Bois H, Heim T, Lund A . Tumor-draining lymph nodes: At the crossroads of metastasis and immunity. Sci Immunol. 2021; 6(63):eabg3551. PMC: 8628268. DOI: 10.1126/sciimmunol.abg3551. View

10.

Griss J, Bauer W, Wagner C, Simon M, Chen M, Grabmeier-Pfistershammer K . B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nat Commun. 2019; 10(1):4186. PMC: 6744450. DOI: 10.1038/s41467-019-12160-2. View

11.

Woeste M, Shrestha R, Geller A, Li S, Montoya-Durango D, Ding C . Irreversible electroporation augments β-glucan induced trained innate immunity for the treatment of pancreatic ductal adenocarcinoma. J Immunother Cancer. 2023; 11(4). PMC: 10124260. DOI: 10.1136/jitc-2022-006221. View

12.

Pandey V, Fleming-Martinez A, Bastea L, Doeppler H, Eisenhauer J, Le T . CXCL10/CXCR3 signaling contributes to an inflammatory microenvironment and its blockade enhances progression of murine pancreatic precancerous lesions. Elife. 2021; 10. PMC: 8360647. DOI: 10.7554/eLife.60646. View

13.

Dascani P, Ding C, Kong X, Tieri D, Hu X, Zhang H . Transcription Factor STAT3 Serves as a Negative Regulator Controlling IgE Class Switching in Mice. Immunohorizons. 2019; 2(11):349-362. DOI: 10.4049/immunohorizons.1800069. View

14.

Singh S, Roszik J, Saini N, Singh V, Bavisi K, Wang Z . B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade. Front Immunol. 2022; 13:794684. PMC: 9204262. DOI: 10.3389/fimmu.2022.794684. View

15.

Liu M, Zhao X, Ma Y, Zhou Y, Deng M, Ma Y . Transcription factor c-Maf is essential for IL-10 gene expression in B cells. Scand J Immunol. 2018; 88(3):e12701. DOI: 10.1111/sji.12701. View

16.

Chibaya L, Murphy K, DeMarco K, Gopalan S, Liu H, Parikh C . EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance. Nat Cancer. 2023; 4(6):872-892. PMC: 10516132. DOI: 10.1038/s43018-023-00553-8. View

17.

Mirlekar B, Wang Y, Li S, Zhou M, Entwistle S, De Buysscher T . Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity. Cell Rep Med. 2022; 3(9):100744. PMC: 9512696. DOI: 10.1016/j.xcrm.2022.100744. View

18.

Spear S, Candido J, McDermott J, Ghirelli C, Maniati E, Beers S . Discrepancies in the Tumor Microenvironment of Spontaneous and Orthotopic Murine Models of Pancreatic Cancer Uncover a New Immunostimulatory Phenotype for B Cells. Front Immunol. 2019; 10:542. PMC: 6445859. DOI: 10.3389/fimmu.2019.00542. View

19.

Ganti S, Albershardt T, Iritani B, Ruddell A . Regulatory B cells preferentially accumulate in tumor-draining lymph nodes and promote tumor growth. Sci Rep. 2015; 5:12255. PMC: 4507466. DOI: 10.1038/srep12255. View

20.

Gunderson A, Kaneda M, Tsujikawa T, Nguyen A, Affara N, Ruffell B . Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer. Cancer Discov. 2015; 6(3):270-85. PMC: 4783268. DOI: 10.1158/2159-8290.CD-15-0827. View